Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease

This publication has 21 references indexed in Scilit:

• Dichotomal role of inhibition of p38 MAPK with SB 203580 in experimental colitis
  Gut, 2002
• A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
  Nature, 2001
• Differential activity and expression of mitogen-activated protein kinases in inflammatory bowel disease
  Gastroenterology, 2001
• Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn’s disease — the mechanisms of action of infliximab
  Alimentary Pharmacology & Therapeutics, 1999
• Role of Interleukin (IL)-2 Receptor β-Chain Subdomains and Shc in p38 Mitogen-activated Protein (MAP) Kinase and p54 MAP Kinase (Stress-activated Protein Kinase/c-Jun N-terminal Kinase) Activation
  Journal of Biological Chemistry, 1999
• A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease
  New England Journal of Medicine, 1997
• CNI-1493 inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency.
  Proceedings of the National Academy of Sciences, 1996
• Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone.
  The Journal of Experimental Medicine, 1996
• Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
  Gastroenterology, 1995
• Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID).
  Gut, 1989